Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The proliferation and activation of microglial cells is a hallmark of several neurodegenerative conditions. This mechanism is regulated by the activation of the colony-stimulating factor 1 receptor (CSF1R), thus providing a target that may prevent the progression of conditions such as Alzheimer’s disease. However, the study of microglial proliferation in Alzheimer’s disease and validation of the efficacy of CSF1R-inhibiting strategies have not yet been reported. In this study we found increased proliferation of microglial cells in human Alzheimer’s disease, in line with an increased upregulation of the CSF1R-dependent pro-mitogenic cascade, correlating with disease severity. Using a transgenic model of Alzheimer’s-like pathology (APPswe, PSEN1dE9; APP/PS1 mice) we define a CSF1R-dependent progressive increase in microglial proliferation, in the proximity of amyloid-β plaques. Prolonged inhibition of CSF1R in APP/PS1 mice by an orally available tyrosine kinase inhibitor (GW2580) resulted in the blockade of microglial proliferation and the shifting of the microglial inflammatory profile to an anti-inflammatory phenotype. Pharmacological targeting of CSF1R in APP/PS1 mice resulted in an improved performance in memory and behavioural tasks and a prevention of synaptic degeneration, although these changes were not correlated with a change in the number of amyloid-β plaques. Our results provide the first proof of the efficacy of CSF1R inhibition in models of Alzheimer’s disease, and validate the application of a therapeutic strategy aimed at modifying CSF1R activation as a promising approach to tackle microglial activation and the progression of Alzheimer’s disease. Microglial proliferation and activation is a hallmark of Alzheimer’s disease. Olmos-Alonso et al. show that microglial proliferation in Alzheimer’s disease tissue correlates with overactivation of the colony-stimulating factor 1 receptor (CSF1R) pathway. CSF1R blockade arrests microglial proliferation and activation in a mouse model of Alzheimer-like pathology and slows disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of microglia did not significantly alter the levels of Aβ38, Aβ40, or Aβ42, in detergent-soluble or -insoluble cortical and thalamic homogenates in either the 4- or 7- month cohorts (Fig. 5a–h), in line with multiple studies showing that CSF1R inhibition does not affect Aβ production/clearance10,27,28.”
From Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting CSF-1R has recently been reported to ameliorate AD pathology in APP/PS1 mice, where inhibition of CSF-1R reduced microglial proliferation and decreased the inflammatory phenotype of microglia around amyloid plaques [35].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial proliferation has been shown to be the main contributor to increased microglial numbers under certain disease states such as ischemia, facial nerve transection, prion disease, and Alzheimer’s disease [42, 61–64].”
From IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the use of these agents is limited in experimental TBI studies, several groups have reported that microglial elimination [via colony-stimulating factor 1 receptor (CSF1R) inhibition] improves behavioral performance and synaptic functioning independent of Aβ accumulation in multiple transgenic mouse models of AD (3xTg, 5xFAD, APP/PS1) (236–238).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [237]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“activated microglia in AD show increased proliferation (63,64) and increased expression of inflammatory markers such as CD36, CD14, CD11c, MHC-II, and iNOS (65,66)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [64]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 5×
“…pathogenesis is supported by recent genome-wide association studies, highlighting immune-related genes such as CR1 (Jun et al., 2010), TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013) or HLA-DRB5–HLA-DRB1 in association with Alzheimer’s disease (European Alzheimer’s Disease et al.,…”
ResultInfluentialVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 5×
“The contribution of inflammation to disease pathogenesis is supported by recent genome-wide association studies, highlighting immune-related genes such as CR1 (Jun et al., 2010), TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013) or HLA-DRB5–HLA-DRB1 in association with Alzheimer’s disease (European Alzheimer’s Dise…”
InfluentialCSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 2×
“The therapeutic potential of CSF1R inhibitors has been suggested in inflammatory diseases, autoimmune dis- orders, bone disease and cancer (Burns and Wilks, 2011; Pyonteck et al., 2013).”
BackgroundMethodNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 4×
“, 2009), together with tangle pathology (Nelson et al., 2012) or neurodegeneration-related biomarkers (Wirth et al.”
BackgroundInfluentialElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“Activated microglia have been demonstrated in transgenic models of Alzheimer’s disease (LaFerla and Oddo, 2005; Jucker, 2010) and have been recently shown to dominate the gene expression landscape of patients with Alzheimer’s disease (Zhang et al., 2013).”
BackgroundMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 2×
“microglia with an activated phenotype (Perry et al., 2010)”
BackgroundSelf-citation
Cited by
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Microglia in Alzheimer’s disease
Hansen, D. V., Hanson, J. E., & Sheng, M. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201709069 · Cited by 1,935
“…understanding the role of microglia in neurodegeneration. mRNA profiles of microglia sorted by flow cytometry from the brains of β-amyloid mouse models show marked changes in expression of hundreds of genes (Orre et al., 2014; Wang et al., 2015; Srinivasan et al., 2016; Keren-Shaul et al., 2017).”
BackgroundDisease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474
ARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
Spangenberg, E., Severson, P. L., Hohsfield, L. A., Crapser, J., Zhang, J., Burton, E. A., Zhang, Y., Spevak, W., Lin, J., Phan, N. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11674-z · Cited by 939
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain
Askew, K., Li, K., Olmos-Alonso, A., Garcia-Moreno, F., Liang, Y., Richardson, P., Tipton, T., Chapman, M. A., Riecken, K., Beccari, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.041 · Cited by 726
Self-citationMitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease
Kwon, H. J., Cha, M.-Y., Kim, D., Kim, D. K., Soh, M., Shin, K., Hyeon, T., & Mook-Jung, I. (2016) · ACS Nano · doi:10.1021/acsnano.5b08045 · Cited by 655
Neuroinflammation in Alzheimer disease
Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., Jacobs, A. H., et al. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01104-7 · Cited by 638
Self-citationA new fate mapping system reveals context-dependent random or clonal expansion of microglia
Tay, T. L., Mai, D., Dautzenberg, J., Fernández-Klett, F., Lin, G., Sagar, Datta, M., Drougard, A., Stempfl, T., Ardura-Fabregat, A., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4547 · Cited by 597
Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice
Shi, Q., Chowdhury, S., Ma, R., Le, K. X., Hong, S., Caldarone, B. J., Stevens, B., & Lemere, C. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6295 · Cited by 593
Late onset Alzheimer’s disease genetics implicates microglial pathways in disease risk
Efthymiou, A. G., & Goate, A. M. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0184-x · Cited by 562
Inflammation: the link between comorbidities, genetics, and Alzheimer’s disease
Newcombe, E. A., Camats-Perna, J., Silva, M. L., Valmas, N., Huat, T. J., & Medeiros, R. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1313-3 · Cited by 532
Synaptic degeneration in Alzheimer disease
Tzioras, M., McGeachan, R. I., Durrant, C. S., & Spires-Jones, T. L. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-022-00749-z · Cited by 504
Chen, S. G., Stribinskis, V., Rane, M. J., Demuth, D. R., Gozal, E., Roberts, A. M., Jagadapillai, R., Liu, R., Choe, K., Shivakumar, B., et al. (2016) · Scientific Reports · doi:10.1038/srep34477 · Cited by 463
Bidirectional Microglia–Neuron Communication in Health and Disease
Szepesi, Z., Manouchehrian, O., Bachiller, S., & Deierborg, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00323 · Cited by 459
“In line with this, disabled microglial proliferation and microglial depletion protects against synapse loss in amyloidosis mouse models but does not necessarily have effect on the formation and maintenance of β-amyloid plaques (Grathwohl et al., 2009; Olmos-Alonso et al., 2016; Spangenberg et al., 2016).”
BackgroundIntegrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2023) · doi:10.1101/2023.05.08.539485 · Cited by 425
Integrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01774-5 · Cited by 397
Neuroinflammation: Microglia and T Cells Get Ready to Tango
Schetters, S. T. T., Gomez-Nicola, D., Garcia-Vallejo, J. J., & Van Kooyk, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01905 · Cited by 382
Self-citationTranscriptional signature in microglia associated with Aβ plaque phagocytosis
Grubman, A., Choo, X. Y., Chew, G., Ouyang, J. F., Sun, G., Croft, N. P., Rossello, F. J., Simmons, R., Buckberry, S., Landin, D. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23111-1 · Cited by 357
Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System
Chitu, V., Gokhan, Ş., Nandi, S., Mehler, M. F., & Stanley, E. R. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.03.005 · Cited by 362
Inflammation in Alzheimer’s disease: Lessons learned from microglia-depletion models
Spangenberg, E. E., & Green, K. N. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.07.003 · Cited by 352
Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome
Tejera, D., Mercan, D., Sanchez‐Caro, J. M., Hanan, M., Greenberg, D., Soreq, H., Latz, E., Golenbock, D., & Heneka, M. T. (2019) · The EMBO Journal · doi:10.15252/embj.2018101064 · Cited by 351
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Henry, R. J., Ritzel, R. M., Barrett, J. P., Doran, S. J., Jiao, Y., Leach, J. B., Szeto, G. L., Wu, J., Stoica, B. A., Faden, A. I., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.2402-19.2020 · Cited by 335
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Hu, Y., Fryatt, G. L., Ghorbani, M., Obst, J., Menassa, D. A., Martin-Estebane, M., Muntslag, T. A. O., Olmos-Alonso, A., Guerrero-Carrasco, M., Thomas, D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109228 · Cited by 298
Self-citationMicroglia in Alzheimer’s disease: pathogenesis, mechanisms, and therapeutic potentials
Miao, J., Ma, H., Yang, Y., Liao, Y., Lin, C., Zheng, J., Yu, M., & Lan, J. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1201982 · Cited by 293
Flores, J., Noël, A., Foveau, B., Lynham, J., Lecrux, C., & LeBlanc, A. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06449-x · Cited by 287
Losurdo, M., Pedrazzoli, M., D'Agostino, C., Elia, C. A., Massenzio, F., Lonati, E., Mauri, M., Rizzi, L., Molteni, L., Bresciani, E., et al. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0327 · Cited by 260
To Kill a Microglia: A Case for CSF1R Inhibitors
Green, K. N., Crapser, J. D., & Hohsfield, L. A. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.07.001 · Cited by 262
Microglial cell loss after ischemic stroke favors brain neutrophil accumulation
Otxoa-de-Amezaga, A., Miró-Mur, F., Pedragosa, J., Gallizioli, M., Justicia, C., Gaja-Capdevila, N., Ruíz-Jaen, F., Salas-Perdomo, A., Bosch, A., Calvo, M., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1954-4 · Cited by 258
Davies, D. S., Ma, J., Jegathees, T., & Goldsbury, C. (2017) · Brain Pathology · doi:10.1111/bpa.12456 · Cited by 251
Clayton, K., Delpech, J. C., Herron, S., Iwahara, N., Ericsson, M., Saito, T., Saido, T. C., Ikezu, S., & Ikezu, T. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00440-9 · Cited by 245
Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk
McQuade, A., & Blurton-Jones, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.045 · Cited by 244
Microglia and Alzheimer’s Disease
Merighi, S., Nigro, M., Travagli, A., & Gessi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112990 · Cited by 236
“Increased proliferation [82,83] and expression of inflammatory markers including CD36, CD14, CD11c, MHC-II, and iNOS [84,85], as well as indicators of the M1 phenotype (such as IL-1, MCP-1, MIP-1, IL-1, TNF, and IL-6), and chemokine receptors are all signs of activated microglia in AD (e.”
BackgroundCSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice
Mancuso, R., Fryatt, G., Cleal, M., Obst, J., Pipi, E., Monzón-Sandoval, J., Ribe, E., Winchester, L., Webber, C., Nevado, A., et al. (2019) · Brain · doi:10.1093/brain/awz241 · Cited by 235
Self-citationMicroglia in Alzheimer’s Disease: Activated, Dysfunctional or Degenerative
Navarro, V., Sanchez-Mejias, E., Jimenez, S., Muñoz-Castro, C., Sanchez-Varo, R., Davila, J. C., Vizuete, M., Gutierrez, A., & Vitorica, J. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00140 · Cited by 229
Alzheimer’s Disease: From Firing Instability to Homeostasis Network Collapse
Frere, S., & Slutsky, I. (2018) · Neuron · doi:10.1016/j.neuron.2017.11.028 · Cited by 237
Role of chronic neuroinflammation in neuroplasticity and cognitive function: A hypothesis
Lecca, D., Jung, Y. J., Scerba, M. T., Hwang, I., Kim, Y. K., Kim, S., Modrow, S., Tweedie, D., Hsueh, S., Liu, D., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12610 · Cited by 218
Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer’s Disease
Lewcock, J. W., Schlepckow, K., Di Paolo, G., Tahirovic, S., Monroe, K. M., & Haass, C. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.029 · Cited by 221
Liu, W., Taso, O., Wang, R., Bayram, S., Graham, A. C., Garcia-Reitboeck, P., Mallach, A., Andrews, W. D., Piers, T. M., Botia, J. A., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa209 · Cited by 214
Microglia Gone Rogue: Impacts on Psychiatric Disorders across the Lifespan
Tay, T. L., Béchade, C., D’Andrea, I., St-Pierre, M.-K., Henry, M. S., Roumier, A., & Tremblay, M.-E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00421 · Cited by 216
Meilandt, W. J., Ngu, H., Gogineni, A., Lalehzadeh, G., Lee, S.-H., Srinivasan, K., Imperio, J., Wu, T., Weber, M., Kruse, A. J., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1871-19.2019 · Cited by 210
“In -amyloid models, the reduction in synapse number requires the presence of microglia since depleting the microglial cell population largely prevents loss of synaptic density (Olmos-Alonso et al., 2016; Spangenberg et al., 2016).”
BackgroundLi, Y., Ritzel, R. M., Khan, N., Cao, T., He, J., Lei, Z., Matyas, J. J., Sabirzhanov, B., Liu, S., Li, H., et al. (2020) · Theranostics · doi:10.7150/thno.49199 · Cited by 209
Liu, J., Li, H., Gong, T., Chen, W., Mao, S., Kong, Y., Yu, J., & Sun, J. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c02807 · Cited by 199
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
Rachmian, N., Medina, S., Cherqui, U., Akiva, H., Deitch, D., Edilbi, D., Croese, T., Salame, T. M., Ramos, J. M. P., Cahalon, L., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01620-8 · Cited by 180
Casali, B. T., MacPherson, K. P., Reed-Geaghan, E. G., & Landreth, G. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104956 · Cited by 186
Targeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
“This concept has gained support in recent preclinical studies in Ab-depositing mouse models: partial elimination of microglia by using pharmacological inhibitors of the Colony Stimulating Factor 1 Receptor (CSF1R) resulted in reduction of total microglia, with an overall shift in microglial phenotypes towards a more a…”
BackgroundResultThe link between chronic pain and Alzheimer’s disease
Cao, S., Fisher, D. W., Yu, T., & Dong, H. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1608-z · Cited by 181
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Yu, T.-W., Lane, H.-Y., & Lin, C.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158208 · Cited by 176
Oosterhof, N., Kuil, L. E., van der Linde, H. C., Burm, S. M., Berdowski, W., van Ijcken, W. F. J., van Swieten, J. C., Hol, E. M., Verheijen, M. H. G., & van Ham, T. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.113 · Cited by 178
“Several studies have shown that pharmacological inhibition of CSF1R causes microglia depletion and that, in mousemodels, it ameliorates neurodegenerative disease-like symptoms by depleting microglia or diminishing their proliferation and activation (Elmore et al., 2014; Olmos-Alonso et al., 2016; Spangenberg et al., 2…”
BackgroundSoluble phospho-tau from Alzheimer’s disease hippocampus drives microglial degeneration
Sanchez-Mejias, E., Navarro, V., Jimenez, S., Sanchez-Mico, M., Sanchez-Varo, R., Nuñez-Diaz, C., Trujillo-Estrada, L., Davila, J. C., Vizuete, M., Gutierrez, A., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1630-5 · Cited by 175
“In this sense, increases in microglial reactivity [32] or, in contrast, pharmacological depletion of microglial cells [32, 36, 53, 63] clearly enhanced or reduced Alzheimer’s disease pathology, respectively, with consequent changes in tau phosphorylation, synaptic strength, and neuronal cell lost.”
BackgroundYoung microglia restore amyloid plaque clearance of aged microglia
Daria, A., Colombo, A., Llovera, G., Hampel, H., Willem, M., Liesz, A., Haass, C., & Tahirovic, S. (2017) · The EMBO Journal · doi:10.15252/embj.201694591 · Cited by 174
Absence of microglia promotes diverse pathologies and early lethality in Alzheimer’s disease mice
Kiani Shabestari, S., Morabito, S., Danhash, E. P., McQuade, A., Sanchez, J. R., Miyoshi, E., Chadarevian, J. P., Claes, C., Coburn, M. A., Hasselmann, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110961 · Cited by 167
Martínez-Muriana, A., Mancuso, R., Francos-Quijorna, I., Olmos-Alonso, A., Osta, R., Perry, V. H., Navarro, X., Gomez-Nicola, D., & López-Vales, R. (2016) · Scientific Reports · doi:10.1038/srep25663 · Cited by 168
Self-citationZhan, L., Krabbe, G., Du, F., Jones, I., Reichert, M. C., Telpoukhovskaia, M., Kodama, L., Wang, C., Cho, S.-H., Sayed, F., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000134 · Cited by 163
CSF1R signaling is a regulator of pathogenesis in progressive MS
Hagan, N., Kane, J. L., Grover, D., Woodworth, L., Madore, C., Saleh, J., Sancho, J., Liu, J., Li, Y., Proto, J., et al. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03084-7 · Cited by 165
Han, J., Chitu, V., Stanley, E. R., Wszolek, Z. K., Karrenbauer, V. D., & Harris, R. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04225-1 · Cited by 161
Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases
Hamilton, J. A., Cook, A. D., & Tak, P. P. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.231 · Cited by 160
Coughlin, J. M., Wang, Y., Minn, I., Bienko, N., Ambinder, E. B., Xu, X., Peters, M. E., Dougherty, J. W., Vranesic, M., Koo, S. M., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3764 · Cited by 160
Sehgal, A., Irvine, K. M., & Hume, D. A. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101509 · Cited by 174
Dysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation
Chu, E., Mychasiuk, R., Hibbs, M. L., & Semple, B. D. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02325-6 · Cited by 152
Glial Contribution to Excitatory and Inhibitory Synapse Loss in Neurodegeneration
Henstridge, C. M., Tzioras, M., & Paolicelli, R. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00063 · Cited by 143
Guo, L., Bertola, D. R., Takanohashi, A., Saito, A., Segawa, Y., Yokota, T., Ishibashi, S., Nishida, Y., Yamamoto, G. L., Franco, J. F. D. S., et al. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.03.004 · Cited by 133
Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy
Clayton, K. A., Van Enoo, A. A., & Ikezu, T. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00680 · Cited by 134
Microglia-Mediated Neuroprotection, TREM2, and Alzheimer’s Disease: Evidence From Optical Imaging
Condello, C., Yuan, P., & Grutzendler, J. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.007 · Cited by 131
Beckmann, N., Giorgetti, E., Neuhaus, A., Zurbruegg, S., Accart, N., Smith, P., Perdoux, J., Perrot, L., Nash, M., Desrayaud, S., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0510-8 · Cited by 131
The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128
Baligács, N., Albertini, G., Borrie, S. C., Serneels, L., Pridans, C., Balusu, S., & De Strooper, B. (2024) · Nature Communications · doi:10.1038/s41467-024-54779-w · Cited by 123
“While ● male ○ female d 1–4-month-old PLX3397-treated App NL-G-F mice some studies suggest that microglia depletion can inhibit plaque formation 24,25 , others report no change 26,27 or even an increase in plaque size 11,28 (Supplementary Table 1).”
Neal, M. L., Fleming, S. M., Budge, K. M., Boyle, A. M., Kim, C., Alam, G., Beier, E. E., Wu, L., & Richardson, J. R. (2020) · The FASEB Journal · doi:10.1096/fj.201900567rr · Cited by 123
Differential contribution of microglia and monocytes in neurodegenerative diseases
Baufeld, C., O’Loughlin, E., Calcagno, N., Madore, C., & Butovsky, O. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1795-7 · Cited by 123
Inflammatory mechanisms in neurodegeneration
Nichols, M. R., St‐Pierre, M., Wendeln, A., Makoni, N. J., Gouwens, L. K., Garrad, E. C., Sohrabi, M., Neher, J. J., Tremblay, M., & Combs, C. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14674 · Cited by 121
The role of innate immunity in Alzheimer's disease
Ennerfelt, H. E., & Lukens, J. R. (2020) · Immunological Reviews · doi:10.1111/imr.12896 · Cited by 119
Gut microbiota–driven brain Aβ amyloidosis in mice requires microglia
Dodiya, H. B., Lutz, H. L., Weigle, I. Q., Patel, P., Michalkiewicz, J., Roman-Santiago, C. J., Zhang, C. M., Liang, Y., Srinath, A., Zhang, X., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20200895 · Cited by 120
“, 2010], APPSWE/PS1DE9+CSF1R inhibitor [GW2580; Olmos-Alonso et al., 2016], P301S+CSF1R-inhibitor [JNJ-527; Mancuso et al.”
Furube, E., Kawai, S., Inagaki, H., Takagi, S., & Miyata, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-20643-3 · Cited by 121
Gerber, Y. N., Saint-Martin, G. P., Bringuier, C. M., Bartolami, S., Goze-Bac, C., Noristani, H. N., & Perrin, F. E. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00368 · Cited by 116
Insulin Signaling Impairment in the Brain as a Risk Factor in Alzheimer’s Disease
Hölscher, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00088 · Cited by 117
Welikovitch, L. A., Do Carmo, S., Maglóczky, Z., Malcolm, J. C., Lőke, J., Klein, W. L., Freund, T., & Cuello, A. C. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914593117 · Cited by 116
“CSF-1 and other components of the CSF-1 signaling pathway are similarly up-regulated in the postmortem AD brain (58).”
BackgroundTansey, K. E., Cameron, D., & Hill, M. J. (2018) · Genome Medicine · doi:10.1186/s13073-018-0523-8 · Cited by 115
Han, J., Zhu, K., Zhang, X., & Harris, R. A. (2019) · Glia · doi:10.1002/glia.23529 · Cited by 112
Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases
Xiang, C., Li, H., & Tang, W. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106566 · Cited by 118
Genetic variability in response to amyloid beta deposition influences Alzheimer’s disease risk
Salih, D. A., Bayram, S., Guelfi, S., Reynolds, R. H., Shoai, M., Ryten, M., Brenton, J. W., Zhang, D., Matarin, M., Botia, J. A., et al. (2019) · Brain Communications · doi:10.1093/braincomms/fcz022 · Cited by 110
Tzioras, M., Daniels, M. J. D., Davies, C., Baxter, P., King, D., McKay, S., Varga, B., Popovic, K., Hernandez, M., Stevenson, A. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101175 · Cited by 105
The spatiotemporal dynamics of microglia across the human lifespan
Menassa, D. A., Muntslag, T. A. O., Martin-Estebané, M., Barry-Carroll, L., Chapman, M. A., Adorjan, I., Tyler, T., Turnbull, B., Rose-Zerilli, M. J. J., Nicoll, J. A. R., et al. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.07.015 · Cited by 104
Liu, Y., Wu, Z., Nakanishi, Y., Ni, J., Hayashi, Y., Takayama, F., Zhou, Y., Kadowaki, T., & Nakanishi, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-12173-1 · Cited by 105
Insights Into the Role of CSF1R in the Central Nervous System and Neurological Disorders
Hu, B., Duan, S., Wang, Z., Li, X., Zhou, Y., Zhang, X., Zhang, Y.-W., Xu, H., & Zheng, H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.789834 · Cited by 104
Microglia and Astrocytes in Alzheimer’s Disease: Significance and Summary of Recent Advances
Deng, Q., Wu, C., Parker, E., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Aging and disease · doi:10.14336/ad.2023.0907 · Cited by 102
“Moreover, the proliferation and activation of microglia in AD tissues is associated with the overactivation of the colony-stimulating factor 1 receptor (CSF1R) pathway [195].”
BackgroundUnique microglia recovery population revealed by single-cell RNAseq following neurodegeneration
Tay, T. L., Sagar, Dautzenberg, J., Grün, D., & Prinz, M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0584-3 · Cited by 99
Interactions between inflammation, sex steroids, and Alzheimer’s disease risk factors
Uchoa, M. F., Moser, V. A., & Pike, C. J. (2016) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2016.09.001 · Cited by 102
Role of microglia in spinal cord injury
Kroner, A., & Almanza, J. R. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134370 · Cited by 107
New Insights into Microglia–Neuron Interactions: A Neuron’s Perspective
Pósfai, B., Cserép, C., Orsolits, B., & Dénes, Á. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2018.04.046 · Cited by 98
Keaney, J., Gasser, J., Gillet, G., Scholz, D., & Kadiu, I. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09839-0 · Cited by 98
“Data presented as mean ± s.d., unpaired t-test, *p < 0.05 (Keren-Shaul et al. 2017; Yin et al. 2017) and studies depleting microglia in AD mouse models (Olmos-Alonso et al. 2016; Spangenberg et al. 2016).”
BackgroundInfluentialThe A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration
Hinkle, J. T., Dawson, V. L., & Dawson, T. M. (2019) · Movement Disorders · doi:10.1002/mds.27718 · Cited by 99
PDE4B as a microglia target to reduce neuroinflammation
Pearse, D. D., & Hughes, Z. A. (2016) · Glia · doi:10.1002/glia.22986 · Cited by 102
Ju, F., Ran, Y., Zhu, L., Cheng, X., Gao, H., Xi, X., Yang, Z., & Zhang, S. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00236 · Cited by 95
Post-Ischaemic Immunological Response in the Brain: Targeting Microglia in Ischaemic Stroke Therapy
Rawlinson, C., Jenkins, S., Thei, L., Dallas, M. L., & Chen, R. (2020) · Brain Sciences · doi:10.3390/brainsci10030159 · Cited by 95
Metadata
- Authors
- Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-Caballero, M., Holscher, C., Perry, V. H., & Gomez-Nicola, D.
- Affiliations
- University of Southampton (GB)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-08
- Volume
- 139
- Issue
- 3
- Pages
- 891-907
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4766375
- OpenAlex
- W2222356562
- Cited by
- 532
- References
- 66
- Citations by year
- 2026: 38 · 2025: 50 · 2024: 50 · 2023: 57 · 2022: 45 · 2021: 79 · 2020: 51 · 2019: 44 · 2018: 51 · 2017: 37 · 2016: 30
- FWCI
- 29.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Brain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Alzheimer's Society
- Medical Research Council (MR/K022687/1)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- CSF1R inhibition, microglial proliferation, Alzheimer's disease, GW2580, tyrosine kinase inhibitors, APP/PS1 mice, amyloid plaques, microglial activation, anti-inflammatory phenotype, synaptic degeneration, memory impairment, neuroinflammation, disease progression
- MeSH terms
- Alzheimer Disease, Animals, Anisoles, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Pyrimidines, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Drug Delivery Systems, Microglia, Disease Progression, Protein Kinase Inhibitors, Cell Proliferation, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.